Company Disclosure

CORONA Remedies Limited submitted a press release containing unaudited financial results for Q2 and half year ended September 30, 2026, pursuant to Regulation 30 of SEBI Listing Regulations.

Financial Performance (₹ in Crores)

Q2 FY27 Performance:

  • Revenue from Operations: ₹441.2 crore (vs. ₹361.1 crore in Q2 FY26, +22.2% YoY)
  • EBITDA: ₹96.0 crore (vs. ₹78.5 crore in Q2 FY26, +22.3% YoY)
  • EBITDA Margin: 21.7% (unchanged from Q2 FY26)
  • Profit After Tax: ₹60.3 crore (vs. ₹52.3 crore in Q2 FY26, +15.3% YoY)
  • PAT Margin: 13.7% (vs. 14.5% in Q2 FY26)

H1 FY27 Performance:

  • Revenue from Operations: ₹863.6 crore (vs. ₹707.7 crore in H1 FY26, +22.0% YoY)
  • EBITDA: ₹189.1 crore (vs. ₹148.2 crore in H1 FY26, +27.5% YoY)
  • EBITDA Margin: 21.9% (vs. 20.9% in H1 FY26)
  • Profit After Tax: ₹120.4 crore (vs. ₹98.5 crore in H1 FY26, +22.2% YoY)
  • PAT Margin: 13.9% (unchanged from H1 FY26)

Note: PAT and PAT margins were lower due to higher depreciation & amortization charges from newly commissioned facilities and brand acquisitions, with revenue contributions expected to build up over coming quarters.

Key Business Highlights

Market Performance:

  • Ranked 14th in Covered Market and 26th in overall Indian Pharmaceutical Market (IPM) as per MAT Sep'26
  • Outperformed IPM growth by 1.9 times for MAT Sep'26
  • Volume growth 2x higher than IPM
  • Pricing 1.5x higher than IPM
  • New Introductions 2.4x higher than IPM

Brand Performance:

  • Now has 4 brands exceeding ₹100 crores in annual sales
  • 1 brand crossed ₹200 crores in annual sales as per MAT Sep'26

Portfolio Performance:

  • Chronic + Semi Chronic contribution: 71.2% in Q2 FY27 (vs. 67.7% in Q2 FY26)
  • Chronic + Semi Chronic growth approximately 350 bps higher than company growth

Regulatory Achievement:

  • Received Good Manufacturing Practice (GMP) certification from Brazil's National Health Surveillance Agency (ANVISA)
  • Certification covers manufacturing facility at Bhayla, Ahmedabad
  • Includes both Oral Solid Dosage (OSD) and Women's Hormone production lines

Management Commentary

Mr. Nirav K. Mehta, Managing Director & CEO, commented:

  • Domestic business grew at 22.9%, well ahead of IPM growth of 12%
  • Chronic portfolio grew at nearly twice the rate of its market segment
  • Growth reflects disciplined execution and focus on long-term strategy
  • Company remains committed to strengthening core therapies, building powerful brands, and driving operational excellence
  • Indian pharmaceutical industry has strong structural demand drivers
  • Company is well positioned to capitalize on opportunities with diversified portfolio, established brands, and expanding market reach